Collaborating Institutes

Strong expertise in the field of cell and gene therapy, HIV and immuno-oncology focusing on developing transformative, multi-indication, platform drugs to change the standard of care of Oncology, HIV and HBV.


Fred Hutchinson Cancer Center unites comprehensive care and advanced research to provide the latest cancer treatment options and accelerate discoveries that prevent, treat and defeat cancer and infectious diseases worldwide. Based in Seattle, Fred Hutch is an independent, nonprofit organization and is the only National Cancer Institute-designated cancer center in Washington.

We have earned a global reputation for our track record of discoveries in cancer, infectious disease and basic research, including important advances in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines.

Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and has network affiliations with hospitals in five states. Fred Hutch also serves as UW Medicine’s cancer program.


Caring Cross is a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and ensuring access to cures for all patients, everywhere.

To enable its mission, Caring Cross is mobilizing a growing community of healthcare professionals, scientists, engineers, community advocates, donors, investors, and business leaders to support the development of technologies and candidate medicines and technologies.

Currently, Caring Cross is advancing several initiatives that aim to improve the accessibility, affordability and applicability of CAR-T technology and stem cell gene therapy. These opportunities include developing and implementing affordable solutions for the manufacture of CAR-T cells, advancing a decentralized, place-of-care cell manufacturing model, and developing its first therapeutic candidate, an Anti-HIV DuoCAR-T Cell Therapy designed to suppress HIV replication and eliminate HIV-expressing cells in people with HIV.